Firefly Neuroscience partners with Next Health on precision cognitive health platform
AIFF•Strategic partnership and platform launch
Firefly Neuroscience entered a strategic partnership with Next Health to launch a precision cognitive health platform for longevity clinics.
The platform combines Firefly’s FDA 510(k)-cleared EEG/ERP brain biomarker technology with personalized physician-guided cognitive peptide protocols.
The partnership targets objective brain-function measurement to personalize, monitor and optimize emerging cognitive therapies, replacing symptom-based assessments.
The launch follows an FDA advisory panel recommendation to ease compounding restrictions for six peptides, including Epitalon and Semax.
The companies plan standardized clinical protocols across Next Health’s expanding clinic network as adoption of quantitative neurodiagnostics accelerates.
